A novel [Mn-2(mu-(C6H5)(2)CHCOO)(2)(bipy)(4)](bipy)(ClO4)(2) complex loaded solid lipid nanoparticles: synthesis, characterization and in vitro cytotoxicity on MCF-7 breast cancer cells


Eskiler G. G., ÇEÇENER G., DİKMEN G., Kani I., Egeli U., TUNCA B.

JOURNAL OF MICROENCAPSULATION, vol.33, no.6, pp.575-584, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 6
  • Publication Date: 2016
  • Doi Number: 10.1080/02652048.2016.1228704
  • Journal Name: JOURNAL OF MICROENCAPSULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.575-584
  • Keywords: Metal-based ligands, Mn(II) complex, 2,2 '-bipyridine, drug delivery systems, solid lipid nanoparticles (SLNs), cancer, DRUG-DELIVERY-SYSTEMS, ANTICANCER DRUGS, MANGANESE(II) COMPLEX, CAFFEIC ACID, FUTURE, FORMULATION, COPPER(II), RESISTANCE, LIGAND
  • Anadolu University Affiliated: Yes

Abstract

Manganese (Mn)-based complexes have been drawing attention due to the fact that they are more effective than other metal complexes. However, the use of Mn(II)-based complexes in medicine remains limited because of certain side effects. The aim of this study was to investigate the cytotoxic and apoptotic effects of a novel Mn(II) complex [Mn-2(mu-(C6H5)(2)CHCOO)(2)(bipy)(4)](bipy)(ClO4)(2) and Mn(II) complex loaded solid lipid nanoparticles (SLNs) on MCF-7 and HUVEC control cells. The average diameter of Mn(II) complex was about 1120 +/- 2.43nm, while the average particle size of Mn(II) complex-SLNs was approximate to 340 +/- 2.27nm. The cytotoxic effects of Mn(II) complex and Mn(II)-SLNs were 86.8 and 66.4%, respectively (p<.05). Additionally, both Mn(II) complex (39.25%) and Mn(II)-SLNs (38.05%) induced apoptosis and increased the arrest of G(0)/G(1) phase. However, Mn(II) complex exerted toxic effects on the HUVEC control cell (63.4%), whereas no toxic effects was observed when treated with Mn(II)-SLNs at 150M. As a consequence, SLNs might be potentially used for metal-based complexes in the treatment of cancer due to reducing size and toxic effects of metal-based complexes.